

Daniel N Cagney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8499441/publications.pdf>

Version: 2024-02-01

55
papers

2,404
citations

394421

19
h-index

214800

47
g-index

56
all docs

56
docs citations

56
times ranked

3330
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on Radiation Therapy for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 77-93.	2.2	5
2	Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: a population- and institutional-level analysis. <i>Neuro-Oncology Practice</i> , 2022, 9, 114-122.	1.6	1
3	Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery. <i>Physics in Medicine and Biology</i> , 2022, 67, 065009.	3.0	2
4	Predictors of long-term survival among patients with brain metastases. <i>Neuro-Oncology</i> , 2022, , .	1.2	2
5	Incidence and Predictors of Neurologic Death in Patients with Brain Metastases. <i>World Neurosurgery</i> , 2022, 162, e401-e415.	1.3	2
6	Evaluation of the response assessment criteria in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2020-2020.	1.6	0
7	Seizures Among Patients With Brain Metastases. <i>Neurology</i> , 2021, 96, .	1.1	12
8	Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. <i>Medical Dosimetry</i> , 2021, 46, 21-28.	0.9	4
9	Development and Implementation of an Online Adaptive Stereotactic Body Radiation Therapy Workflow for Treatment of Intracardiac Metastasis. <i>Practical Radiation Oncology</i> , 2021, 11, e395-e401.	2.1	3
10	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e213304.	5.9	4
11	Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). <i>Radiotherapy and Oncology</i> , 2021, 160, 159-165.	0.6	67
12	NIMG-24. RANO CRITERIA DETECTS EARLY PROGRESSION SOONER THAN MODIFIED RANO CRITERIA IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi133-vi133.	1.2	0
13	Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. <i>Journal of the National Cancer Institute</i> , 2020, 112, 229-237.	6.3	15
14	Advanced Practice Providers in Radiation Oncology. <i>Practical Radiation Oncology</i> , 2020, 10, e192-e198.	2.1	6
15	Utility of claims data for identification of date of diagnosis of brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 575-576.	1.2	12
16	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-“small cell lung cancer and melanoma brain metastases. <i>Cancer</i> , 2020, 126, 5274-5282.	4.1	19
17	MRI in Radiation Oncology After the COVID-19 Pandemic. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 397-399.	0.8	0
18	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. <i>Journal of Clinical Oncology</i> , 2020, 38, 3773-3784.	1.6	223

#	ARTICLE	IF	CITATIONS
19	Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. <i>World Neurosurgery</i> , 2020, 139, 226-231.	1.3	5
20	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. <i>JAMA Oncology</i> , 2020, 6, 1028.	7.1	122
21	Hospice Utilization in Elderly Patients With Brain Metastases. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1251-1258.	6.3	7
22	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. <i>Neuro-Oncology</i> , 2020, 22, 1339-1347.	1.2	27
23	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. <i>Neuro-Oncology</i> , 2020, 22, 1359-1367.	1.2	49
24	A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. <i>Neuro-Oncology</i> , 2020, 22, 918-927.	1.2	15
25	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii43-ii44.	1.2	3
26	Use of a healthy volunteer imaging program to optimize clinical implementation of stereotactic MR-guided adaptive radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 16, 70-76.	1.9	2
27	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2020, 22, ii44-ii44.	1.2	5
28	RADT-25. EVALUATING LYMPHOCYTE COUNTS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION. <i>Neuro-Oncology</i> , 2020, 22, ii186-ii187.	1.2	0
29	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 39-45.	1.7	26
30	MLTI-12. TIMING OF SYSTEMIC THERAPY ADMINISTRATION RELATIVE TO STEREOTACTIC RADIOSURGERY AND DEVELOPMENT OF RADIATION NECROSIS IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i16-i17.	0.7	0
31	Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases. <i>JAMA Oncology</i> , 2019, 5, 703.	7.1	63
32	Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 171-179.	2.5	15
33	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 355-363.	2.9	13
34	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 142-151.	0.8	118
35	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. <i>World Neurosurgery</i> , 2019, 122, e1557-e1561.	1.3	17
36	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. <i>Cureus</i> , 2019, 11, e4726.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. <i>Radiotherapy and Oncology</i> , 2018, 126, 511-518.	0.6	18
38	The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. <i>Irish Journal of Medical Science</i> , 2018, 187, 887-894.	1.5	0
39	Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. <i>JAMA Oncology</i> , 2018, 4, 1123.	7.1	238
40	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 1162-1172.	1.2	92
41	Assessing the utility of a prognostication model to predict 1-year mortality in patients undergoing radiation therapy for spinal metastases. <i>Spine Journal</i> , 2018, 18, 935-940.	1.3	22
42	Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1001.	7.1	44
43	Evolution of induction chemotherapy in the pre- and post-taxane era for locally advanced laryngeal cancer: A National Cancer Data Base analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18080-e18080.	1.6	1
44	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 344-351.	0.8	143
45	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. <i>Neuro-Oncology</i> , 2017, 19, 1511-1521.	1.2	483
46	Whole brain radiotherapy for non-small cell lung cancer. <i>Lancet</i> , The, 2017, 389, 1394-1395.	13.7	2
47	Brain Metastases in Newly Diagnosed Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1069.	7.1	224
48	The cost and value of glioblastoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 657-659.	2.4	10
49	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103.	0.6	51
50	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. <i>Journal of Neuro-Oncology</i> , 2016, 129, 389-393.	2.9	7
51	Normal tissue considerations and dose-volume constraints in the moderately hypofractionated treatment of non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 423-431.	0.6	24
52	Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism". <i>New England Journal of Medicine</i> , 2016, 375, 196-198.	27.0	138
53	Acral Metastasis from Head and Neck Squamous Cell Carcinoma. <i>Journal of Case Reports</i> , 2015, 5, 219-221.	0.1	0
54	Economic Impact of Prescreening on Gastroenterology Outpatient Clinic Practice. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e76-e79.	2.2	5

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of colonic stenting for malignant disease in the elderly. International Journal of Colorectal Disease, 2010, 25, 747-750.	2.2	32